UroGen Pharma Ltd.
URGN · XNASCIK 1668243fmd_172CHMPENZ9DZPX22QESYG5KT7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2026, 41 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 18 | 8 | 1 | 0 | 12 | 48 | 64 | 83 | 90 | 110 |
| Cost of revenue | 0 | 1 | 2 | – | 1 | 5 | 8 | 9 | 9 | 12 |
| Gross profit | 18 | 8 | (1) | 0 | 11 | 43 | 57 | 73 | 82 | 97 |
| Research and development | – | 19 | 37 | 49 | 47 | 48 | 53 | 46 | 57 | 67 |
| Selling, general and administrative | – | – | – | 60 | 90 | 88 | 83 | 93 | 121 | 155 |
| Total operating expenses | – | 28 | 77 | 109 | – | – | – | – | – | – |
| Operating income | 1 | (20) | (77) | (109) | (127) | (92) | (79) | (66) | (97) | (125) |
| Interest and investment income | – | – | – | 5 | 2 | 0 | 1 | 3 | 9 | 6 |
| Other non-operating income (expense) | – | 0 | (0) | (0) | – | (0) | 0 | 1 | (0) | (1) |
| Income before taxes | (2) | (20) | (76) | (105) | (125) | (109) | (108) | (98) | (124) | (153) |
| Income tax expense | – | 0 | 0 | – | 3 | 1 | 2 | 4 | 3 | 0 |
| Net income from continuing operations | – | (20) | (76) | – | (128) | (111) | (110) | (102) | (127) | (153) |
| Net income | (2) | (20) | (76) | (105) | (128) | (111) | (110) | (102) | (127) | (153) |
| Net income to common shareholders | (4) | (21) | (76) | (105) | (128) | – | – | – | – | – |